ARCHIVES

Executive Committee, Board of Scientific Advisors concur.

This article is from The Cancer Letter archive.

Vol. 30 No. 01 | January 2, 2004

Download PDF Visit The Full Archive

Related Articles

FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response

July 29, 2011

Pertuzumab Delays Progression In HER2-Positive Breast Cancer

August 26, 2011

In Brief: NCCS to hold Candlelight Vigil Sept. 25; Moffit Wins Chemistry-Biology Grants

September 17, 1999

Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial

May 31, 2013

Also: NCCN Committee Reaffirms Clinical Guideline Covering Avastin for Breast Cancer Indication

July 22, 2011

NCI Cancer Prevention Fellowship Program

April 28, 2000